Myelin Oligodendrocyte Glycoprotein (MOG) Associated Diseases: Updates in Pediatric Practice

Area of Science:

• Neuroimmunology
• Neurology
• Cell Biology

Background:

• Myelin oligodendrocyte glycoprotein (MOG) is a key protein in the central nervous system's myelin sheath.
• Anti-MOG antibodies (MOG-Abs) are increasingly recognized in demyelinating and white matter disorders.
• MOG-associated disease (MOGAD) often affects pediatric populations and can be relapsing.

Purpose of the Study:

• To review the current literature on MOG-associated disease (MOGAD).
• To discuss emerging clinical phenotypes, treatment strategies, and prognosis for MOGAD.
• To provide insights into future research directions for MOG-Abs and MOGAD.

Main Methods:

• Literature review of studies on MOG-associated disease.
• Analysis of clinical phenotypes, treatment outcomes, and prognostic factors.
• Synthesis of current understanding and identification of knowledge gaps.

Main Results:

• MOGAD is associated with a spectrum of neurological conditions, primarily demyelinating disorders.
• The pathogenic role of MOG-Abs versus their utility as biomarkers is under ongoing investigation.
• Pediatric populations show a predilection for MOGAD, which can exhibit a relapsing course.

Conclusions:

• Further research is needed to elucidate the precise role of MOG-Abs in disease pathogenesis.
• Understanding MOGAD's clinical spectrum and optimizing treatment are crucial for patient outcomes.
• Future studies should focus on clarifying MOG-Abs' pathogenicity and developing targeted therapies.